Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 12Thyroid Cancer, Papillary 5Adenocarcinoma, Follicular 5Differentiated Thyroid Cancer 4Recombinant Human Thyroid Stimulating Hormone 1Neoplasm Metastasis 1Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation 1Low Risk Differentiated Thyroid Cancer 1Hypothyroidism 1Heterotaxy Syndrome 1Head and Neck Neoplasms 1DTC - Differentiated Thyroid Cancer 1

Interventions

trametinib 1dabrafenib 1Thyrotropin Alfa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation × Thyrotropin Alfa × Head & Neck × Clear all
NCT03244956 2026-03-23

MERAIODE

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Completed
40 enrolled
EndocrineHead & Neck

Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡